{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:05:51Z","timestamp":1790334351604,"version":"4.1.0"},"reference-count":150,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH\/National Heart, Lung, and Blood Institute","award":["T32-HL007093"],"award-info":[{"award-number":["T32-HL007093"]}]},{"name":"Jos\u00e9 Carreras\/E. Donnall Thomas Endowed Chair for Cancer Research","award":["T32-HL007093"],"award-info":[{"award-number":["T32-HL007093"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Allogeneic hematopoietic cell transplantation (HCT) remains an important curative-intent treatment for many patients with acute myeloid leukemia (AML), but AML recurrence after allografting is common. Many factors associated with relapse after allogeneic HCT have been identified over the years. Central among these is measurable (\u201cminimal\u201d) residual disease (MRD) as detected by multiparameter flow cytometry, quantitative polymerase chain reaction, and\/or next-generation sequencing. Demonstration of a strong, independent prognostic role of pre- and early post-HCT MRD has raised hopes MRD could also serve as a predictive biomarker to inform treatment decision-making, with emerging data indicating the potential value to guide candidacy assessment for allografting as a post-remission treatment strategy, the selection of conditioning intensity, use of small molecule inhibitors as post-HCT maintenance therapy, and preemptive infusion of donor lymphocytes. Monitoring for leukemia recurrence after HCT and surrogacy for treatment response are other considerations for the clinical use of MRD data. In this review, we will outline the current landscape of MRD as a biomarker for patients with AML undergoing HCT and discuss areas of uncertainty and ongoing research.<\/jats:p>","DOI":"10.3390\/cells14040290","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T07:48:22Z","timestamp":1739778502000},"page":"290","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8480-6260","authenticated-orcid":false,"given":"Margery","family":"Gang","sequence":"first","affiliation":[{"name":"Hematology and Oncology Fellowship Program, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8176-6371","authenticated-orcid":false,"given":"Megan","family":"Othus","sequence":"additional","affiliation":[{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3341","authenticated-orcid":false,"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA"},{"name":"Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA 98195, USA"},{"name":"Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Loke, J., Vyas, H., and Craddock, C. (2021). Optimizing transplant approaches and post-transplant strategies for patients with acute myeloid leukemia. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.666091"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Loke, J., Buka, R., and Craddock, C. (2021). Allogeneic stem cell transplantation for acute myeloid leukemia: Who, when, and how?. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.659595"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101466","DOI":"10.1016\/j.beha.2023.101466","article-title":"Allogeneic hematopoietic cell transplantation in acute myeloid leukemia","volume":"36","author":"Magee","year":"2023","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1200\/JCO.22.02868","article-title":"What influences the decision to proceed to transplant for patients with AML in first remission?","volume":"41","author":"DeWolf","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/CCO.0000000000000992","article-title":"Recent advances in allogeneic transplantation for acute myeloid leukemia","volume":"35","author":"Montoro","year":"2023","journal-title":"Curr. Opin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/leu.2017.113","article-title":"Measurable residual disease testing in acute myeloid leukaemia","volume":"31","author":"Hourigan","year":"2017","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3324\/haematol.2022.282034","article-title":"The present and future of measurable residual disease testing in acute myeloid leukemia","volume":"107","author":"Blachly","year":"2022","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood.2020006219","article-title":"Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow","volume":"137","author":"Godwin","year":"2021","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Xue, Y., Xia, X., Liu, X., Zheng, Y., Gu, H., and Wang, X. (2024). Applications of circulating tumor DNA in myelodysplastic syndromes and acute myeloid leukemia: Promises and challenges. Front. Biosci., 29.","DOI":"10.31083\/j.fbl2902086"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Butler, J.T., Yashar, W.M., and Swords, R. (Am. J. Hematol., 2025). Breaking the bone marrow barrier: Peripheral blood as a gateway to measurable residual disease detection in acute myelogenous leukemia, Am. J. Hematol., in press.","DOI":"10.1002\/ajh.27586"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/bloodadvances.2019001181","article-title":"Single-cell mutational profiling enhances the clinical evaluation of AML MRD","volume":"4","author":"Ediriwickrema","year":"2020","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"eadg0488","DOI":"10.1126\/sciadv.adg0488","article-title":"Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia","volume":"9","author":"Robinson","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1097\/HS9.0000000000000676","article-title":"Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: Experience of the European LeukemiaNet MRD Working Party","volume":"6","author":"Tettero","year":"2022","journal-title":"Hemasphere"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41375-023-02084-8","article-title":"Perspective on measurable residual disease testing in acute myeloid leukemia","volume":"38","author":"Walter","year":"2024","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41375-024-02158-1","article-title":"Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia","volume":"38","author":"Tettero","year":"2024","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1078-0432.CCR-22-2237","article-title":"Prognostic impact of unsupervised early assessment of bulk and leukemic stem cell measurable residual disease in acute myeloid leukemia","volume":"29","author":"Canali","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s43856-024-00700-x","article-title":"Computational assessment of measurable residual disease in acute myeloid leukemia using mixture models","volume":"4","author":"Mocking","year":"2024","journal-title":"Commun. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","article-title":"CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia","volume":"33","author":"Zeijlemaker","year":"2019","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood.2021014604","article-title":"An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: A prospective study","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"ref_22","first-page":"2657","article-title":"Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial","volume":"141","author":"Ngai","year":"2023","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Matthes, T. (2024). Phenotypic analysis of hematopoietic stem and progenitor cell populations in acute myeloid leukemia based on spectral flow cytometry, a 20-color panel, and unsupervised learning algorithms. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052847"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/blood-2010-09-303685","article-title":"Towards individualized follow-up in adult acute myeloid leukemia in remission","volume":"117","author":"Hokland","year":"2011","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: Results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin","year":"2012","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","article-title":"The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML","volume":"122","author":"Shayegi","year":"2013","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/leu.2017.200","article-title":"DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia","volume":"32","author":"Gaidzik","year":"2018","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3324\/haematol.2020.260133","article-title":"Minimal residual disease monitoring in acute myeloid leukemia with non-A\/B\/D-NPM1 mutations by digital polymerase chain reaction: Feasibility and clinical use","volume":"106","author":"Lesieur","year":"2021","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e390010","DOI":"10.1200\/EDBK_390010","article-title":"Using measurable residual disease to optimize management of AML, ALL, and chronic myeloid leukemia","volume":"43","author":"Dekker","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Yoest, J.M., Shirai, C.L., and Duncavage, E.J. (2020). Sequencing-based measurable residual disease testing in acute myeloid leukemia. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00249"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Hong","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Grob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2017.77.6757","article-title":"Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia","volume":"36","author":"Morita","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_35","first-page":"1000106","article-title":"Accuracy of next generation sequencing platforms","volume":"1","author":"Fox","year":"2014","journal-title":"Next Gener. Seq. Appl."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrg.2017.117","article-title":"Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations","volume":"19","author":"Salk","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41409-019-0729-4","article-title":"Statistics and measurable residual disease (MRD) testing: Uses and abuses in hematopoietic cell transplantation","volume":"55","author":"Othus","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-021-01230-4","article-title":"Measurable residual disease as a biomarker in acute myeloid leukemia: Theoretical and practical considerations","volume":"35","author":"Walter","year":"2021","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.seminhematol.2018.08.009","article-title":"Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR","volume":"56","author":"Versluis","year":"2019","journal-title":"Semin. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood.2020007626","article-title":"Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin","volume":"137","author":"Schmalbrock","year":"2021","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"32","author":"Blanche","year":"2013","journal-title":"Stat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/aje\/kwh101","article-title":"Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker","volume":"159","author":"Pepe","year":"2004","journal-title":"Am. J. Epidemiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-024-02378-5","article-title":"Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)","volume":"38","author":"Othus","year":"2024","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.2019002959","article-title":"Molecular MRD status and outcome after transplantation in NPM1-mutated AML","volume":"135","author":"Dillon","year":"2020","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Wang, M.M., Huang, S.M., Huang, Y.H., Zhang, J., Li, H.Y., Ge, S.S., Wan, C.L., Wang, M., Liu, H.H., and Cao, H.Y. (2024). Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations. Bone Marrow Transpl., in press.","DOI":"10.1038\/s41409-024-02495-w"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood.2024026605","article-title":"Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia","volume":"144","author":"Loo","year":"2024","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e35717","DOI":"10.1002\/cncr.35717","article-title":"Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a-rearranged acute myeloid leukemia","volume":"131","author":"Wang","year":"2025","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41409-024-02447-4","article-title":"Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Gui","year":"2025","journal-title":"Bone Marrow Transpl."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41409-024-02449-2","article-title":"Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Gui","year":"2025","journal-title":"Bone Marrow Transpl."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e2200559","DOI":"10.1200\/PO.22.00559","article-title":"Persistent molecular disease in adult patients with AML evaluated with whole-exome and targeted error-corrected DNA sequencing","volume":"7","author":"Slade","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: A systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1038\/s41375-022-01692-0","article-title":"Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: A systematic review and meta-analysis","volume":"36","author":"Short","year":"2022","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/bmt.2012.139","article-title":"Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia","volume":"48","author":"Buckley","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: A meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ajh.24632","article-title":"Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation","volume":"92","author":"Gaballa","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.bbmt.2017.03.017","article-title":"Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation","volume":"23","author":"Getta","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","article-title":"Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00277-020-04026-1","article-title":"Pre-transplant FLT3\/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation","volume":"99","author":"Helbig","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.2022016567","article-title":"Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome","volume":"140","author":"Loo","year":"2022","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"101468","DOI":"10.1016\/j.beha.2023.101468","article-title":"Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia","volume":"36","author":"Wong","year":"2023","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1007\/s00277-024-06017-y","article-title":"Measurable residual disease assessment prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes: A 20-year monocentric study","volume":"103","author":"Wery","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood.2021014804","article-title":"Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML","volume":"139","author":"Paras","year":"2022","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/bloodadvances.2024013214","article-title":"Measurable residual disease as predictor of post-day +100 relapses following allografting in adult AML","volume":"9","author":"Ali","year":"2025","journal-title":"Blood Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.bbmt.2018.02.003","article-title":"Early post-transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemia","volume":"24","author":"Shah","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood.2023022697","article-title":"Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation","volume":"144","author":"Wienecke","year":"2024","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Teich, K., Stadler, M., Gabdoulline, R., Kandarp, J., Wienecke, C., Heida, B., Klement, P., B\u00fcttner, K., Venturini, L., and Wichmann, M. (2023). MRD as biomarker for response to donor lymphocyte infusion after allogeneic hematopoietic cell transplantation in patients with AML. Cancers, 15.","DOI":"10.3390\/cancers15153911"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1088.e1","DOI":"10.1016\/j.jtct.2024.08.008","article-title":"Dynamic relapse prediction by peripheral blood WT1mRNA after allogeneic hematopoietic cell transplantation for myeloid neoplasms","volume":"30","author":"Nakako","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.2023.283520","article-title":"Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia","volume":"109","author":"Dillon","year":"2024","journal-title":"Haematologica"},{"key":"ref_70","first-page":"273","article-title":"Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"108","author":"Othus","year":"2023","journal-title":"Haematologica"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1200\/JCO.2011.39.6499","article-title":"Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories","volume":"30","author":"Cornelissen","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: A study by the Acute Leukemia French Association Group","volume":"35","author":"Balsat","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.2019001425","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): Results from the AML Study Group","volume":"134","author":"Agrawal","year":"2019","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/bjh.19917","article-title":"Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia-related mutations in first remission","volume":"206","author":"Jiang","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Frisch, A., Ganzel, C., Ofran, Y., Krayem, B., Haran, A., Vainstein, V., Aumann, S., Even-Zohar, N.G., and Nachmias, B. Post-relapse outcomes of older patients with NPM1-mutated AML are favorable with allo transplant in second remission. Eur. J. Haematol., 2024. in press.","DOI":"10.1111\/ejh.14375"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/leu.2016.46","article-title":"Pre- and post-transplant quantification of measurable (\u2018minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia","volume":"30","author":"Zhou","year":"2016","journal-title":"Leukemia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.clml.2024.03.009","article-title":"SOHO state of the art updates and next questions: Pre-emptive therapy at molecular measurable residual disease failure in acute myeloid leukemia","volume":"24","author":"Tedjaseputra","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_82","first-page":"694","article-title":"Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients with AML: Results from the NCRI AML18 trial","volume":"43","author":"Russell","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3324\/haematol.2011.044388","article-title":"Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse","volume":"96","author":"Sockel","year":"2011","journal-title":"Haematologica"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/bjh.16722","article-title":"Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia","volume":"192","author":"Tiong","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjh.18887","article-title":"A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure","volume":"202","author":"Sartor","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1200\/JCO.23.01599","article-title":"Targeting molecular measurable residual disease and low-blast relapse in AML with venetoclax and low-dose cytarabine: A prospective phase II study (VALDAC)","volume":"42","author":"Tiong","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/bloodadvances.2016000760","article-title":"Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia","volume":"1","author":"Quek","year":"2016","journal-title":"Blood Adv."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","article-title":"Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)","volume":"19","author":"Aoudjhane","year":"2005","journal-title":"Leukemia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.leu.2404037","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity","volume":"20","author":"Shimoni","year":"2006","journal-title":"Leukemia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.bbmt.2006.06.003","article-title":"Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome","volume":"12","author":"Alyea","year":"2006","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia","volume":"27","author":"Labopin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transpl."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2352-3026(18)30022-X","article-title":"Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: Retrospective follow-up of an open-label, randomised phase 3 trial","volume":"5","author":"Fasslrinner","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.25211","article-title":"Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation","volume":"93","author":"Gilleece","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Morsink, L.M., Sandmaier, B.M., Othus, M., Palmieri, R., Granot, N., Bezerra, E.D., Wood, B.L., Mielcarek, M., Schoch, G., and Davis, C. (2020). Conditioning intensity, pre-transplant flow cytometric measurable residual disease, and outcome in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Cancers, 12.","DOI":"10.3390\/cancers12092339"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.beha.2013.10.010","article-title":"Which donor or graft source should you choose for the strongest GVL? Is there really any difference","volume":"26","author":"Weisdorf","year":"2013","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/bloodadvances.2016002386","article-title":"Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1","volume":"1","author":"Versluis","year":"2017","journal-title":"Blood Adv."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/hematology.2022000327","article-title":"In 2022, which is preferred: Haploidentical or cord transplant?","volume":"2022","author":"Nagler","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3109\/10428194.2015.1102241","article-title":"The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission","volume":"57","author":"Zheng","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41409-018-0300-8","article-title":"The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts","volume":"54","author":"Liu","year":"2019","journal-title":"Bone Marrow Transpl."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/s41375-019-0686-3","article-title":"Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: A prospective multicentre cohort study","volume":"34","author":"Yu","year":"2020","journal-title":"Leukemia"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1182\/bloodadvances.2022009253","article-title":"T-cell replete cord transplants give superior outcomes in high-risk and relapsed\/refractory pediatric myeloid malignancy","volume":"7","author":"Horgan","year":"2023","journal-title":"Blood Adv."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41375-024-02497-z","article-title":"Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia","volume":"39","author":"Orvain","year":"2025","journal-title":"Leukemia"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Ferrara, F., and Picardi, A. (2019). Is there still a role for autologous stem cell transplantation for the treatment of acute myeloid leukemia?. Cancers, 12.","DOI":"10.3390\/cancers12010059"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2991\/chi.k.210703.002","article-title":"History and development of autologous stem cell transplantation for acute myeloid leukemia","volume":"3","author":"Gorin","year":"2021","journal-title":"Clin. Hematol. Int."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.2018886960","article-title":"GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia","volume":"134","author":"Venditti","year":"2019","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s41409-023-02070-9","article-title":"Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT","volume":"58","author":"Chen","year":"2023","journal-title":"Bone Marrow Transpl."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.bmt.1701672","article-title":"Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation","volume":"23","author":"Elmaagacli","year":"1999","journal-title":"Bone Marrow Transpl."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/sj.leu.2404828","article-title":"Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Oran","year":"2007","journal-title":"Leukemia"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/hematology.2022000353","article-title":"Transplant in AML with measurable residual disease: Proceed or defer?","volume":"2022","author":"Craddock","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/bmt.2013.2","article-title":"CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT","volume":"48","author":"Rosenow","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bbmt.2014.12.029","article-title":"Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies","volume":"21","author":"Horn","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/trf.12524","article-title":"Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"54","author":"Tan","year":"2014","journal-title":"Transfusion"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1182\/blood-2007-02-072470","article-title":"Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia","volume":"109","author":"Dominietto","year":"2007","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2011-09-380386","article-title":"Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2016.07.010","article-title":"Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation","volume":"49","author":"Ghobadi","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood.2021012412","article-title":"How I treat with maintenance therapy after allogeneic HCT","volume":"141","author":"DeFilipp","year":"2023","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cncr.25500","article-title":"Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: A dose and schedule finding study","volume":"116","author":"Giralt","year":"2010","journal-title":"Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/bjh.13248","article-title":"Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia","volume":"169","author":"Oshikawa","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","article-title":"Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: Long-term follow-up of an open-label, multicentre, randomised, phase 3 trial","volume":"10","author":"Xuan","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): A single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"Fenaux","year":"2023","journal-title":"Blood Adv."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","article-title":"Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies","volume":"6","author":"Fathi","year":"2022","journal-title":"Blood Adv."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1078-0432.CCR-23-0182","article-title":"Multicenter phase I trial of ivosidenib as maintenance treatment following allogeneic hematopoietic cell transplantation for IDH1-mutated acute myeloid leukemia","volume":"29","author":"Fathi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.jtct.2023.12.029","article-title":"Multicenter pilot clinical trial of enasidenib as maintenance therapy after allogeneic hematopoietic cell transplantation (alloHCT) in patients with acute myeloid leukemia (AML) varrying IDH2 mutations [abstract]","volume":"30","author":"Salhotra","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood-2009-04-212530","article-title":"Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias","volume":"115","author":"Ommen","year":"2010","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"E408","DOI":"10.1002\/ajh.26698","article-title":"Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission","volume":"97","author":"Short","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1200\/JCO.2008.20.1533","article-title":"Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy","volume":"27","author":"Grimwade","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bjh.16857","article-title":"Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: Outcome after preemptive intervention based on measurable residual disease","volume":"191","author":"Bataller","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/s41375-023-01994-x","article-title":"FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML","volume":"37","author":"Othman","year":"2023","journal-title":"Leukemia"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): An open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","article-title":"MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: Results from the AML05 multicenter trial","volume":"121","author":"Zhu","year":"2013","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-023-00941-4","article-title":"Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study","volume":"13","author":"Xu","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_148","unstructured":"Food and Drug Administration (2020). Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment\u2014Guidance for Industry, Food and Drug Administration."},{"key":"ref_149","unstructured":"Food and Drug Administration (2022). Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment\u2014Guidance for Industry, Food and Drug Administration."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood.2021013404","article-title":"Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status","volume":"139","author":"Roboz","year":"2022","journal-title":"Blood"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/4\/290\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:35:21Z","timestamp":1760027721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/4\/290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":150,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cells14040290"],"URL":"https:\/\/doi.org\/10.3390\/cells14040290","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]}}}